Fmr LLC Purchases 68,881 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

FMR LLC grew its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 3.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,944,831 shares of the biotechnology company's stock after purchasing an additional 68,881 shares during the period. FMR LLC owned about 0.83% of ADMA Biologics worth $38,877,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. USA Financial Formulas increased its holdings in ADMA Biologics by 8.6% during the 3rd quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company's stock valued at $136,000 after purchasing an additional 539 shares during the period. Vontobel Holding Ltd. grew its holdings in shares of ADMA Biologics by 7.0% during the 3rd quarter. Vontobel Holding Ltd. now owns 13,643 shares of the biotechnology company's stock worth $273,000 after acquiring an additional 888 shares during the period. Hollencrest Capital Management purchased a new position in shares of ADMA Biologics during the 3rd quarter worth approximately $30,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of ADMA Biologics by 21.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,430 shares of the biotechnology company's stock worth $163,000 after acquiring an additional 1,509 shares during the period. Finally, Larson Financial Group LLC purchased a new position in shares of ADMA Biologics during the 3rd quarter worth approximately $31,000. Institutional investors own 75.68% of the company's stock.

ADMA Biologics Stock Performance

Shares of NASDAQ ADMA traded down $0.81 during midday trading on Monday, hitting $19.01. 3,041,177 shares of the stock traded hands, compared to its average volume of 3,606,414. The firm has a 50-day moving average of $19.10 and a two-hundred day moving average of $15.76. The firm has a market capitalization of $4.49 billion, a P/E ratio of 70.79 and a beta of 0.70. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. ADMA Biologics, Inc. has a one year low of $3.60 and a one year high of $23.64.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of $0.13 by $0.02. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The company had revenue of $119.84 million for the quarter, compared to analysts' expectations of $107.25 million. During the same period last year, the firm earned $0.01 EPS. On average, equities analysts forecast that ADMA Biologics, Inc. will post 0.52 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Brad L. Tade sold 15,000 shares of the stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $21.15, for a total value of $317,250.00. Following the completion of the transaction, the chief financial officer now owns 199,433 shares of the company's stock, valued at approximately $4,218,007.95. This trade represents a 7.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.70% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

ADMA has been the topic of a number of research analyst reports. Raymond James upped their target price on ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a report on Friday, November 8th. Cantor Fitzgerald restated an "overweight" rating and issued a $20.00 price target on shares of ADMA Biologics in a research note on Friday, September 20th. Finally, HC Wainwright upped their price objective on ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a research report on Friday, November 8th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.